<div>This webinar brings together industry leaders from Biophore and IQGEN-X to share their perspective on entrepreneurship in the pharma industry, challenges they face and how Clarivate has played a pivotal role in partnering with them by providing insightful intelligence through their journey to success.</div>
Across all trial phases (I-III), 53% of trial protocols need to be amended after initiation. These amendments mean delays in critical timelines that can quickly cause you to fall behind in the race to beat the competition. Each day a drug is delayed from the market, sponsors lose up to $8m. So how can you increase the odds of designing your trial correctly the first time?
In this webinar, we look at tens of thousands of trial designs over the past decade – protocols, site identification, biomarker selection, and more – to uncover answers to questions that will position your clinical trial for success from day one:
As pharmaceutical companies expand the number of regions within which clinical, manufacturing and marketing authorization is performed, the demands for managing regulatory change intensifies. Coupled with the growing diversity in product make-up (biologics, cell and gene therapies, companion diagnostics, delivery devices, digital health), the depth and breadth of regulatory changes can cripple Quality and Regulatory functions. The process of managing regulatory change is burdensome, costly, and prone to compliance risk. The task of changing SOPs to comply with regulatory change in multiple global regions is anything but simple, and industry leaders look to change the paradigm completely.
Although regulatory functions have not widely applied artificial intelligence to streamline and automate processes, AI and digital automation have the potential to support and transform this business need. Ultimately, this will allow pharmaceutical companies to react to changes in regulatory requirements in a nimble and highly efficient manner, to reduce compliance missteps and avoid risks and fines. In this webinar, Clarivate partnered with APACMed to discuss a new approach that leverages technology, AI and automation to streamline SOP monitoring and updating and increase efficiencies.
Key points that will be covered:
New target identification and validation is one of the hardest jobs in pharmacology, as thousands of researchers have found out to their dismay.
In this webinar, we shared a workflow for new target identification and validation which is more effective, faster and reliable.
This webinar will guide how one can answer the following questions:
Since the time of the genomic revolution, networks have been key to understanding biology in health and disease. However, building networks and reconstructing disease pathways have always been a time-consuming and challenging processes. Artificial intelligence (AI) has been applied to nearly all aspects of drug development, including network construction and target identification.
By applying AI to these workflows, researchers can not only quickly and efficiently process the mountains of data generated from experimental analysis but also support confident, data-driven go/no-go decisions for greater success down the drug development pipeline. In this webinar, we discuss how companies can accelerate preclinical development, save time and money and speed time to market through AI.
Watch this on-demand webinar to learn:
Network biology has become a powerful approach for academic research and drug discovery, bringing together OMICs data, pathway and network prior knowledge databases, and tools for OMICs data analysis. Significant effort is being invested in OMICs data generation, and major databases exist with manually curated network and pathway information to guide analysis. However, OMICs data and the supporting network resources require advanced computational methods to drive scientific discovery.
The COVID-19 pandemic has changed the way we work and live virtually overnight, making it increasingly difficult to stay on top of the deal-making landscape, track competitive clinical development activities and find new opportunities for expansion influenced by the shifting COVID-19 landscape. But working from home doesn’t mean your pipeline analysis should be compromised.
COVID-19 is sparking all kinds of innovation – from testing and treatments to drug repurposing and vaccines. Local health authorities are releasing new guidance at breakneck speed, making it increasingly difficult to stay on top of it all.
From monitoring protocol and patient eligibility criteria changes to evaluating the feasibility of alternate sites and tracking peers’ activities to inform your own strategy, COVID-19 is disrupting clinical development and making it more challenging than ever to understand the trial landscape.
As scientists develop vaccines and treatments to meet the urgent needs of those affected by COVID-19, it’s becoming increasingly difficult to cut through the noise and keep track of all the new therapies, vaccines, targets and experimental results to inform your research.
The newly launched Cortellis Drugs to Watch 2020 list identifies eleven drugs that are set to enter the market in 2020 and reach more than $1 billion in sales by 2024. Therapies targeting central nervous system indications and cancer dominate the list. The list highlights yet another strong showing by orphan drug status or other designations, as well. Great majority of the medicines are for indications crowded with competitors. Thus, there will be substantial pressure on these therapeutics to differentiate from existing products. We will also discuss the latest development on COVID-19 and what we know so far.
The newly launched ‘2020 Cortellis Drugs to Watch’ list identifies 11 drugs that are set to enter the market in 2020 and reach more than $1 billion in sales by 2024. Only 3 of 11 drugs are focusing on oncology and it is evident that pharmaceutical companies are also investing on other indications and focusing more on clinical unmet needs and conditions with current treatments hampered by safety, efficacy, convenience or other issues.
Artificial intelligence (AI) has evolved significantly over the past decade, but it is still not clear whether these advanced computational tools can live up to the buzz. Within drug development, specifically, toxicology is one area where AI systems have the potential to revolutionize the process. By applying AI to a variety of workflows, researchers can not only predict potential toxicity or off-target effects but also process the mountains of data generated from experimental analysis in a quick and efficient way that is meaningful and free of human bias. AI and machine learning (ML) algorithms may allow scientists to gain a deeper understanding of the mechanisms related to toxicity and subtle differences in the the genetic makeup that influence the maximum tolerated dose or efficacy of drug in different individuals. Ultimately, AI can speed up pre-clinical development, save companies immense amounts of time and money, and get to market quicker.
This webinar will take a closer look at the use and success of applications of AI and ML in drug development and best practices around implementation. We will tackle the big questions, including:
Digital health has become one of the most innovative and technologically advanced arms of healthcare. Significant advancements, such as big data, telemedicine, mHealth and virtual reality, have pushed pharma to seek new partnerships and more actively engage in digital transformation. 2019 saw significant deal making activity in the digital health space, with many partnerships involving pharma.
This webinar will explore the disruptive influence digital health is having on the traditional deals landscape and how partnerships are fueling digital health innovation.
This webinar will provide insights on:
As Pharmaceutical companies expand the number of regions within which clinical, manufacturing and marketing authorization is performed, the demands for managing regulatory change intensifies. Coupled with the growing diversity in product make-up (biologics, cell and gene therapies, companion diagnostics, delivery devices, digital health), the depth and breadth of regulatory changes can cripple Quality and Regulatory functions. The process of managing regulatory change is burdensome, costly, and prone to compliance risk. The task of changing SOPs to comply with regulatory change in multiple global regions is anything but simple, and industry leaders look to change the paradigm completely.
Recent manufacturing advances have led the FDA to proclaim that continuous manufacturing is one of the important tools to modernize the pharma industry through its faster, more efficient processes. The move to continuous manufacturing involves more than just equipment and manufacturing processes. Regulatory compliance must also be considered. Get up to speed on the latest regulatory developments as we look forward to 2020. We’ll discuss key trends and changes in manufacturing that pharma companies should anticipate for a successful year.
MetaCore is a web-based bioinformatics suite that allows researchers to upload data analysis results from experiments such as microarray, next generation sequencing, metabolic, SAGE, siRNA, microRNA, and screening.
MetaCore provides biological insight from OMICs data as well as a search interface for the underlying systems biology knowledgebase along with functional analysis of experimental data based on a proprietary, manually curated database of human protein-protein, protein-DNA and protein-compound interactions, metabolic and signaling pathways and the effects of bioactive molecules.
This webinar provides an introduction to the various capabilities of this software suite and the various ways it can accelerate innovation in your research.
Gain insight into global and regional regulatory trends of 2019. Understand which were the most impactful to the industry and reflect on the ramifications for your business.
Learn how you can better evaluate targets to avoid wasting resources and missing opportunities while minimizing risks. Watch this webinar to discover best practice approaches and data-driven options.
To be successful and stay competitive, pharma and biotech companies often look to expand into new markets. Expansion introduces new challenges with regulatory compliance and data integrity regardless of expansion type. Tracking and locating all the key pieces of information needed to successfully launch in new markets can be time-consuming and error prone. Often, nuances of regulations and specific requirements are missed when they vary so greatly in each potential market. You need a strategic advantage to increase your success and compliance in new markets.
The API and generic dose industries continue to face significant challenges from disruptive forces, such as customer consolidation and increasing competition in local and regulated markets. Additionally, innovator pipelines are shifting evermore away from simple small molecule drugs to complex specialty-driven medicines and biologic therapies. However, these market dynamics offer opportunities for emerging companies to accelerate their growth and even claim leadership positions. This webinar presents insights into upcoming generic product opportunities around the world and the strategies for successfully unlocking new value over the next 5 years.
Consolidation of distributors and marketers have an adverse impact on many generic players in Indian Pharmaceutical space. Larger API manufacturers are still able to manage due to market diversification, however small players are acutely impacted. Learn how Newport can support API manufacturers in identifying new markets for their APIs where API consumption is growing.
The complexity of global pharmaceutical regulatory management is both painful and multi-faceted having impact on both clinical and regulatory departments. Health Authority requirements for more transparency from sponsors and investigators has shaped the demand for open publication of clinical trial data.
In this webinar, our experts cover the leading factors that contribute to clinical attrition, discuss a number of factors associated with trial endpoint success and explore specific strategies related to effective trial amendments.
Using Cortellis tools and data, Jamie Munro, Global Practice Leader for Portfolio and Licensing with Clarivate Analytics digs deeper into the investment landscape for neuroscience, looking at deals, M&A, and VC investment. A closer examination of Alzheimer’s disease development, with setbacks and outlook, will also be covered.
This webinar will introduce Clarivate Analytics’ new Medical Devices and IVDs Regulatory Comparison Module. With this new module, you can now dramatically simplify the regulatory research process by compiling data on all product life cycle regulatory topics, allowing you to exhaustively compare on that topic within different countries and between product types.
In this webinar, you’ll learn about new tools that are now available to identify and prioritize novel targets for NAFLD and NASH, creating a path for drug developers towards a first-in-class treatment.
How the Year’s Top Licensing and M&A Transactions Are Changing the Industry Landscape
This session will explore trial design components in the rare disease space. Have they changed over time to align with the need for simplified design in order to be more accessible to the rare disease population? Our clinical solutions expert will discuss closing the gaps in data intelligence collection and improving efficiencies.
This webinar will provide insights into the use of Integrity in accelerating research and innovation by providing:
In this webinar, featured speakers demonstrate new ways in which publicly available non-small-cell lung cancer (NSCLC) datasets can be examined in order to find novel approaches to targeting the disease. Specifically, they discuss how quick and easy it can be (with the right tools) to examine the novelty of your target and the importance of doing so. The speakers demonstrate tools to find evidence for core known tumour suppressive mechanisms to be potential targets for NSCLC.
In this webinar, Clarivate Analytics’ experts look at the dynamics of drug development a different way, using gold standard Cortellis content, innovative predictive modeling and powerful Centre for Medicines Research (CMR) data to help companies learn from the industry’s failures as well as its successes to improve R&D productivity.
The goal of nanomedicine is to precisely control medical devices at the nanometer scale. Regulation of nanotechnology in medical devices is inconsistent across national jurisdictions in major global markets. Our discussion aims to help organizations understand some key differences in how nanoscale devices and materials are regulated.
In this webinar we are going to discuss how high-throughput experimental approach and pathway analysis can be complemented with associated long-term clinical annotation comprising drug response and expression changes in patients based on recent scientific publications.
Join Clarivate’s Life Sciences experts for a review of regulatory challenges in Sub-Saharan African (SSA) and how to overcome them.
Our experts will dig into the strategies behind last year’s biggest deals and key portfolio decisions. You’ll hear a breakdown by company, therapeutic area and region. You’ll get insight on the region where life sciences dealmaking is rapidly growing. We’ll also take you on a deeper dive into the oncology drug development landscape: Are the drivers in place for its continued dominance in 2019?
In this webinar, you will gain more insights into the report. Understand the top drugs expected to launch in 2019 and achieve blockbuster sales of >$1 billion by 2023.
Seven drugs are set to enter the market in 2019 and achieve blockbuster status by 2023. Therapies targeting diseases characterized by genetic disorder and/or excessive immune response (including autoimmunity) dominate the list, with six agents out of the seven, and a strong showing by orphan drugs and breakthrough treatments, as well.
Pharma investment in oncology is far and above all other therapeutic areas, with dealmaking and partnering a core strategy in that investment. In just the last 4 years, oncology deal values totaled a whopping $331 billion. From the top 20 pharma companies to small start-ups, oncology is pulling investment from across life sciences.
This webinar will focus on regulatory challenges in Indian Pharmaceutical Industry and current regulatory environment . Further, we will also discuss using Cortellis CMC intelligence – Compare key facts and CMC requirements in countries like US, Brazil, China and India.
This webinar will focus on advanced search features of Newport, a Cortellis solution which support in identifying right APIs and dose formulations to be added in product portfolio.
Behind each blockbuster is a story 12 to 15 years in the making. Three of the blockbuster drugs are for rare and orphan diseases. Until recently, the monies raised selling the drug to a small patient population did not cover the development costs and these drugs were rarely developed. This has changed in recent years as now almost a third of drugs currently on the market for rare diseases now generate more than $1B in sales annually.